[
  {
    "ts": null,
    "headline": "Dividend Stock Portfolio for Retirement: Pfizer’s (PFE) Reliable Payouts",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the Best Retirement Stocks for a Dividend Stock Portfolio. Pfizer Inc. (NYSE:PFE) is an American multinational pharmaceutical and biotech company. The last three years have been challenging for its investors. The company’s COVID-19 vaccine and treatment initially sent the stock soaring during the pandemic, but once demand peaked, the […]",
    "url": "https://finnhub.io/api/news?id=cec400234d5c562c2a5888d47401f87c275ea489f8dbf18ecdfff3acf1cbddd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758729845,
      "headline": "Dividend Stock Portfolio for Retirement: Pfizer’s (PFE) Reliable Payouts",
      "id": 136866179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is included among the Best Retirement Stocks for a Dividend Stock Portfolio. Pfizer Inc. (NYSE:PFE) is an American multinational pharmaceutical and biotech company. The last three years have been challenging for its investors. The company’s COVID-19 vaccine and treatment initially sent the stock soaring during the pandemic, but once demand peaked, the […]",
      "url": "https://finnhub.io/api/news?id=cec400234d5c562c2a5888d47401f87c275ea489f8dbf18ecdfff3acf1cbddd0"
    }
  },
  {
    "ts": null,
    "headline": "Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations",
    "summary": "Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Rachel James-Owens as Vice President, Corporate Communications & Media Relations. Rachel brings over 20 years of global pharmaceut",
    "url": "https://finnhub.io/api/news?id=ad6c50c334084ee4c55c8725f99ac8330df6bc839ba3f3987ca4a3bd39894e9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758726000,
      "headline": "Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations",
      "id": 136861792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Rachel James-Owens as Vice President, Corporate Communications & Media Relations. Rachel brings over 20 years of global pharmaceut",
      "url": "https://finnhub.io/api/news?id=ad6c50c334084ee4c55c8725f99ac8330df6bc839ba3f3987ca4a3bd39894e9a"
    }
  },
  {
    "ts": null,
    "headline": "Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls",
    "summary": "Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=953c1f292e07560657ee70497bd84c20e8023bd5693614d906f4e5ca7f59ff8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758720993,
      "headline": "Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls",
      "id": 136861445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=953c1f292e07560657ee70497bd84c20e8023bd5693614d906f4e5ca7f59ff8a"
    }
  },
  {
    "ts": null,
    "headline": "The Smartest Dividend Stock to Buy With $1,000 Right Now",
    "summary": "Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.",
    "url": "https://finnhub.io/api/news?id=ebc306ebeb1bb9c44e3e8327380a59c0d6187d4366d3fb09bafe16897e87e9d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758714300,
      "headline": "The Smartest Dividend Stock to Buy With $1,000 Right Now",
      "id": 136861679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.",
      "url": "https://finnhub.io/api/news?id=ebc306ebeb1bb9c44e3e8327380a59c0d6187d4366d3fb09bafe16897e87e9d4"
    }
  },
  {
    "ts": null,
    "headline": "With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns",
    "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
    "url": "https://finnhub.io/api/news?id=ab79202b0c72b74ea8a21244f25715ccaffbc145b4c62fdc66de743b7f5d7ed9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758711611,
      "headline": "With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns",
      "id": 136861795,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
      "url": "https://finnhub.io/api/news?id=ab79202b0c72b74ea8a21244f25715ccaffbc145b4c62fdc66de743b7f5d7ed9"
    }
  },
  {
    "ts": null,
    "headline": "Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?",
    "summary": "Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.",
    "url": "https://finnhub.io/api/news?id=f73e4f7aad65520c627f3639c2d37b68e2251997ba3ab14fa53ee612befff926",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758710100,
      "headline": "Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?",
      "id": 136861796,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.",
      "url": "https://finnhub.io/api/news?id=f73e4f7aad65520c627f3639c2d37b68e2251997ba3ab14fa53ee612befff926"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc is Wall Street Wrong to Give Up on This Comeback Story?",
    "summary": "Pfizer's Story Isn't Over -- It's Just Quieter Than It Used to Be",
    "url": "https://finnhub.io/api/news?id=1b3d96c7f498b98835dcfbc43b52d7c72e9aa0ef09b60a34791b80ebe3266b81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758705378,
      "headline": "Pfizer Inc is Wall Street Wrong to Give Up on This Comeback Story?",
      "id": 136861797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's Story Isn't Over -- It's Just Quieter Than It Used to Be",
      "url": "https://finnhub.io/api/news?id=1b3d96c7f498b98835dcfbc43b52d7c72e9aa0ef09b60a34791b80ebe3266b81"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Pfizer Be in 5 Years?",
    "summary": "The pharma giant may be heading for a new era of growth.",
    "url": "https://finnhub.io/api/news?id=94ef047918e6fe6cfad1998e6559f4ac38b7fa0044e7458f1ab54a9c94f0752e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758700500,
      "headline": "Where Will Pfizer Be in 5 Years?",
      "id": 136861798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma giant may be heading for a new era of growth.",
      "url": "https://finnhub.io/api/news?id=94ef047918e6fe6cfad1998e6559f4ac38b7fa0044e7458f1ab54a9c94f0752e"
    }
  }
]